Literature DB >> 26292977

A role for 12/15-lipoxygenase-derived proresolving mediators in postoperative ileus: protectin DX-regulated neutrophil extravasation.

Kathy Stein1, Melissa Stoffels1, Mariola Lysson1, Bianca Schneiker1, Oliver Dewald1, Gerhard Krönke1, Jörg C Kalff1, Sven Wehner2.   

Abstract

Resolution of inflammation is an active counter-regulatory mechanism involving polyunsaturated fatty acid-derived proresolving lipid mediators. Postoperative intestinal motility disturbances, clinically known as postoperative ileus, occur frequently after abdominal surgery and are mediated by a complex inflammation of the intestinal muscularis externa. Herein, we tested the hypothesis that proresolving lipid mediators are involved in the resolution of postoperative ileus. In a standardized experimental model of postoperative ileus, we detected strong expression of 12/15-lipoxygenase within the postoperative muscularis externa of C57BL/6 mice, predominately located within CX3CR1(+)/Ly6C(+) infiltrating monocytes rather than Ly6G(+) neutrophils. Mass spectrometry analyses demonstrated that a 12/15-lipoxygenase increase was accompanied by production of docosahexaenoic acid-derived lipid mediators, particularly protectin DX and resolvin D2, and their common precursor 17-hydroxy docosahexaenoic acid. Perioperative administration of protectin DX, but not resolvin D2 diminished blood-derived leukocyte infiltration into the surgically manipulated muscularis externa and improved the gastrointestinal motility. Flow cytometry analyses showed impaired Ly6G(+)/Ly6C(+) neutrophil extravasation after protectin DX treatment, whereas Ly6G(-)/Ly6C(+) monocyte numbers were not affected. 12/15-lipoxygenase-deficient mice, lacking endogenous protectin DX synthesis, demonstrated increased postoperative leukocyte levels. Preoperative intravenous administration of a docosahexaenoic acid-rich lipid emulsion reduced postoperative leukocyte infiltration in wild-type mice but failed in 12/15-lipoxygenase-deficient mice mice. Protectin DX application reduced leukocyte influx and rescued 12/15-lipoxygenase-deficient mice mice from postoperative ileus. In conclusion, our results show that 12/15-lipoxygenase mediates postoperative ileus resolution via production of proresolving docosahexaenoic acid-derived protectin DX. Perioperative, parenteral protectin DX or docosahexaenoic acid supplementation, as well as modulation of the 12/15-lipoxygenase pathway, may be instrumental in prevention of postoperative ileus. © Society for Leukocyte Biology.

Entities:  

Keywords:  lipid; monocytes; resolution

Mesh:

Substances:

Year:  2015        PMID: 26292977     DOI: 10.1189/jlb.3HI0515-189R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  14 in total

Review 1.  Resident macrophages in the healthy and inflamed intestinal muscularis externa.

Authors:  Sven Wehner; Daniel Robert Engel
Journal:  Pflugers Arch       Date:  2017-02-24       Impact factor: 3.657

Review 2.  Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.

Authors:  Charles N Serhan; Bruce D Levy
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 3.  Intestinal Macrophages in Resolving Inflammation.

Authors:  Ashley M Hine; P'ng Loke
Journal:  J Immunol       Date:  2019-08-01       Impact factor: 5.422

4.  15-Lipoxygenase worsens renal fibrosis, inflammation, and metabolism in a murine model of ureteral obstruction.

Authors:  John R Montford; Colin Bauer; Jeremy Rahkola; Julie A Reisz; Deanna Floyd; Katharina Hopp; Danielle E Soranno; Jelena Klawitter; Mary C M Weiser-Evans; Raphael Nemenoff; Sarah Faubel; Seth B Furgeson
Journal:  Am J Physiol Renal Physiol       Date:  2021-12-06

5.  Intestinal epithelial PKM2 serves as a safeguard against experimental colitis via activating β-catenin signaling.

Authors:  Xinlei Sun; Li Yao; Hongwei Liang; Dong Wang; Yueqin He; Yao Wei; Lei Ye; Kai Wang; Limin Li; Jiangning Chen; Chen-Yu Zhang; Guifang Xu; Fangyu Wang; Ke Zen
Journal:  Mucosal Immunol       Date:  2019-08-28       Impact factor: 7.313

6.  Leukocyte-Derived Interleukin-10 Aggravates Postoperative Ileus.

Authors:  Kathy Stein; Mariola Lysson; Beatrix Schumak; Tim Vilz; Sabine Specht; Jürgen Heesemann; Axel Roers; Jörg C Kalff; Sven Wehner
Journal:  Front Immunol       Date:  2018-11-13       Impact factor: 7.561

7.  12/15-Lipoxygenase Regulates IL-33-Induced Eosinophilic Airway Inflammation in Mice.

Authors:  Jun Miyata; Yoshiyuki Yokokura; Kazuyo Moro; Hiroyuki Arai; Koichi Fukunaga; Makoto Arita
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

8.  Protectin DX Exhibits Protective Effects in Mouse Model of Lipopolysaccharide-Induced Acute Lung Injury.

Authors:  Wen Tan; Lin Chen; Ya-Xin Wang; Li-Sha Hu; Wei Xiong; You Shang; Shang-Long Yao
Journal:  Chin Med J (Engl)       Date:  2018-05-20       Impact factor: 2.628

9.  Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response.

Authors:  Yael Haberman; Rebekah Karns; Phillip J Dexheimer; Melanie Schirmer; Judith Somekh; Ingrid Jurickova; Tzipi Braun; Elizabeth Novak; Laura Bauman; Margaret H Collins; Angela Mo; Michael J Rosen; Erin Bonkowski; Nathan Gotman; Alison Marquis; Mason Nistel; Paul A Rufo; Susan S Baker; Cary G Sauer; James Markowitz; Marian D Pfefferkorn; Joel R Rosh; Brendan M Boyle; David R Mack; Robert N Baldassano; Sapana Shah; Neal S Leleiko; Melvin B Heyman; Anne M Grifiths; Ashish S Patel; Joshua D Noe; Bruce J Aronow; Subra Kugathasan; Thomas D Walters; Greg Gibson; Sonia Davis Thomas; Kevin Mollen; Shai Shen-Orr; Curtis Huttenhower; Ramnik J Xavier; Jeffrey S Hyams; Lee A Denson
Journal:  Nat Commun       Date:  2019-01-03       Impact factor: 14.919

Review 10.  The Protectin Family of Specialized Pro-resolving Mediators: Potent Immunoresolvents Enabling Innovative Approaches to Target Obesity and Diabetes.

Authors:  Trond Vidar Hansen; Anders Vik; Charles N Serhan
Journal:  Front Pharmacol       Date:  2019-01-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.